Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15084336 | 0.82 | ALDH1A1 (0.60) | ALDH1A1KDM4EMAPK1NPSR1RECQL | |
| SCHEMBL15081960 | 0.76 | ALDH1A1 (0.41) | ALDH1A1KDM4ELMNAL3MBTL1POLB | |
| SCHEMBL10679421 | 0.76 | ALDH1A1 (0.55) | ALDH1A1KDM4ELMNAPOLBGAA | |
| SCHEMBL15081949 | 0.76 | TSHR (0.44) | ALDH1A1MAPK1 | |
| SCHEMBL19368232 | 0.76 | TSHR (0.44) | ALDH1A1MAPK1 | |
| SCHEMBL15081956 | 0.75 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPK1NPSR1LMNA | |
| SCHEMBL17967807 | 0.74 | KDM4E (0.52) | ALDH1A1KDM4EMAPK1NPSR1RECQL | |
| SCHEMBL28590754 | 0.74 | KDM4E (0.52) | ALDH1A1KDM4EMAPK1NPSR1RECQL | |
| SCHEMBL15081948 | 0.74 | KMT2A (0.49) | ALDH1A1KDM4EHTTMAPK1LMNA | |
| SCHEMBL15081951 | 0.74 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | ALDH1A1 781/4885KDM4E 3317/4885HTT 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.